Enliven officer may sell $591K in stock

Enliven Therapeutics, Inc. (ELVN) received a notice under Rule 144 that officer Benjamin Hohl may sell up to 12,036 shares of common stock, with an aggregate market value of $591,208.32, through broker Jefferies LLC.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. (ELVN) received a notice under Rule 144 that officer Benjamin Hohl may sell up to 12,036 shares of common stock, with an aggregate market value of $591,208.32, through broker Jefferies LLC. The company reports 73,000,000 shares of common stock outstanding as of this notice.

The shares relate to 2,036 long shares from previously exercised options dated December 13, 2024 and 10,000 shares from a stock option exercise dated February 13, 2024. The notice also lists prior sales of 6,018 shares each month on June 17, July 17, and August 17, 2026, under the same arrangement.

All proposed and prior sales are stated to be made pursuant to a previously signed Rule 10b5-1 selling plan adopted on March 18, 2026, with representations regarding material non-public information made as of that adoption date.

Key Figures

Shares to be sold under Rule 144: 12,036 shares Aggregate market value of shares to be sold: $591,208.32 Shares outstanding: 73,000,000 shares +4 more

7 metrics

Shares to be sold under Rule 144 12,036 shares Maximum common shares covered by the notice

Aggregate market value of shares to be sold $591,208.32 Value of the 12,036 shares referenced in the notice

Shares outstanding 73,000,000 shares Common shares outstanding for Enliven Therapeutics referenced in the notice

Prior monthly sale June 17, 2026 6,018 shares; $263,577.27 Sale of ELVN shares reported for June 17, 2026

Prior monthly sale July 17, 2026 6,018 shares; $316,780.36 Sale of ELVN shares reported for July 17, 2026

Prior monthly sale August 17, 2026 6,018 shares; $352,551.29 Sale of ELVN shares reported for August 17, 2026

10b5-1 plan adoption date March 18, 2026 Date of the previously signed/adopted 10b5-1 selling plan

Key Terms

Rule 144, 10b5-1 Selling plan, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 Selling plan regulatory

"All sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan"

aggregate market value financial

"12036 | 591208.32 | 73000000"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ELVN by Benjamin Hohl disclose?

It discloses that officer Benjamin Hohl may sell up to 12,036 shares of Enliven Therapeutics common stock under Rule 144, through Jefferies LLC, with an aggregate market value of $591,208.32, based on the information in the notice.

How many Enliven Therapeutics (ELVN) shares are covered by this Rule 144 notice?

The notice covers up to 12,036 shares of ELVN common stock, consisting of 2,036 long shares from previously exercised options on December 13, 2024 and 10,000 shares from a stock option exercise on February 13, 2024.

What past ELVN share sales by Benjamin Hohl are reported in the last three months?

The filing reports three sales of 6,018 shares each on June 17, 2026, July 17, 2026, and August 17, 2026, with reported proceeds of $263,577.27, $316,780.36, and $352,551.29, respectively.

Is the ELVN Form 144 selling activity under a Rule 10b5-1 plan?

Yes. The notice states that all sales are to be made pursuant to a previously signed or adopted Rule 10b5-1 selling plan dated March 18, 2026, with representations regarding material non-public information made as of that date.

How many Enliven Therapeutics (ELVN) shares are outstanding according to this notice?

The notice lists 73,000,000 shares of Enliven Therapeutics common stock as outstanding in connection with the Rule 144 disclosure. This figure is provided as context for the potential sale.

Which broker is handling the potential ELVN share sales in this Form 144?

The broker identified is Jefferies LLC, located at 520 Madison Avenue, 4th Floor, New York, NY 10022, in connection with the potential sale of 12,036 ELVN common shares described in the Rule 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:34 PM Accepted by SEC EDGAR 09/17/2026 - 04:33 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001882764
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	205 PARK ROAD BURLINGAME CALIFORNIA 94010
Phone	650-547-5814
Name of Person for Whose Account the Securities are To Be Sold	Hohl Benjamin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue, 4th Floor New York NY 10022	12036	591208.32	73000000	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/13/2024	Long shares from previous exercised options	Enliven Therapeutics			2036	12/13/2024	N/A
Common	02/13/2024	Stock Option Exercise	Enliven Therapeutics			10000	02/13/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Benjamin Hohl 205 Park Road Burlingame CA 94010	Enliven Therapeutics	06/17/2026	6018	263577.27
Benjamin Hohl 205 Park Road Burlingame CA 94010	Enliven Therapeutics	07/17/2026	6018	316780.36
Benjamin Hohl 205 Park Road Burlingame CA 94010	Enliven Therapeutics	08/17/2026	6018	352551.29

144: Remarks and Signature

Remarks	All sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 3/18/2026 and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	09/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Benjamin Hohl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)